Treating mood disorders during pregnancy: Safety considerations

Drug Safety

Volumn 28, Issue 8, 2005, Pages 695-706

  Eberhard Gran, Malin ^a   Eskild, Anne ^a,b   Opjordsmoen, Stein ^b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CITALOPRAM; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FOLIC ACID; LAMOTRIGINE; LITHIUM; MIRTAZAPINE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OXAZEPAM; PAROXETINE; PSYCHOTROPIC AGENT; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE;

ABDOMINAL PAIN; AGITATION; BIPOLAR DISORDER; BRAIN HEMORRHAGE; CLEFT FACE; CLINICAL TRIAL; COGNITIVE DEFECT; CONGENITAL HEART DISEASE; CONGENITAL MALFORMATION; CYANOSIS; DEPRESSION; DEVELOPMENTAL DISORDER; DRUG INTOXICATION; DRUG POTENCY; DRUG SAFETY; EBSTEIN ANOMALY; ELECTROCONVULSIVE THERAPY; EPILEPSY; FACE MALFORMATION; FETUS HYPOXIA; FETUS MALFORMATION; FETUS WASTAGE; GENERALIZED ANXIETY DISORDER; HUMAN; HYPOTHERMIA; INFANTILE HYPOTONIA; LETHARGY; LOW BIRTH WEIGHT; MANIA; META ANALYSIS; MOOD DISORDER; MUSCLE HYPOTONIA; NEURAL TUBE DEFECT; NEWBORN DISEASE; ORTHOSTATIC HYPOTENSION; PERINATAL MORBIDITY; PHOBIA; PREGNANCY; PREMATURITY; PRIORITY JOURNAL; PSYCHOTHERAPY; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY TRACT DISEASE; REVIEW; SIDE EFFECT; SPONTANEOUS ABORTION; STILLBIRTH; TERATOGENICITY; UTERUS CONTRACTION; VAGINA BLEEDING; WITHDRAWAL SYNDROME;

EID: 23644455489     PISSN: 01145916     EISSN: 01145916     Source Type: Journal    
DOI: 10.2165/00002018-200528080-00004     Document Type: Review

References (118)

1. Paffenbarger R. Epidemiological aspects of mental illness associated with childbearing. In: Brockington I, Kumar R, editors. Motherhood and mental illness. London: Academic Press, 1982: 19-36
2. Altshuler L, Hendrick V, Cohen L. Course of mood and anxiety disorders during pregnancy and the postpartum period. J Clin Psychiatry 1998; 59: 29-33
3. Evans J, Heron J, Francomb H, et al. Cohort study of depressed mood during pregnancy and after childbirth. BMJ 2001; 323: 257-60
4. Eberhard-Gran M, Tambs K, Opjordsmoen S, et al. Depression during pregnancy and after delivery: a repeated measurement study. J Psychosom Obstet Gynecol 2004; 25: 15-21
5. Johanson R, Chapman G, Murray L, et al. The North Stafford-shire Maternity Hospital prospective study of pregnancy-asso-ciated depression. J Psychosom Obstet Gynaecol 2000; 21: 93-7
6. Josefsson A, Berg G, Nordin C, et al. Prevalence of depressive symptoms in late pregnancy and postpartum. Acta Obstet Gynecol Scand 2001; 80: 251-5
7. Brockington I, Cernick K, Schofield E, et al. Puerperal psychosis. Arch Gen Psychiatry 1981; 38: 829-33
8. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry 1987; 150: 662-73
9. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. J Affect Disord 1998; 50: 143-51
10. Brockington I. Postpartum psychiatric disorders. Lancet 2004; 363: 303-10
11. Watson JP, Elliot SA, Rugg AJ. Psychiatric disorder in pregnancy and the first postnatal year. Br J Psychiatry 1984; 144: 453-62
12. Kumar R, Robson KM. A prospective study of emotional disorders in child-bearing women. Br J Psychiatry 1984; 144: 35-47
13. Zuckerman B, Amaro H, Bauchner H, et al. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 1989; 160: 1107-11
14. Peacock JL, Bland JM, Andersen HR. Preterm delivery: effects of socioeconomic factors, psychological stress, smoking, alcohol, and caffeine. BMJ 1995; 311: 531-5
15. Pollack H, Lantz PM, Frohna JG. Maternal smoking and adverse birth outcomes among singletons and twins. Am J Public Health 2000; 90: 395-400
16. Pritchard C, Teo P. Preterm birth, low birth weight, and the stressfulness of the household role for pregnant women. Soc Sci Med 1994; 38: 89-96
17. Rini C, Dunkel-Schetter C, Wadhwa P, et al. Psychological adaptation and birth outcomes: the role of personal resources, stress, and sociocultural context in pregnancy. Health Psychol 1999; 18: 333-45
18. Teixeira J, Fisk N, Glover V. Association between maternal anxiety in pregnancy and increased uterine artery resistance index: cohort based study. BMJ 1999; 318: 153-7
19. Copper R, Goldenberg R, Das A, et al. The preterm prediction study: maternal stress is associated with spontaneous preterm birth at less than thirty-five weeks' gestation. Am J Obstet Gynecol 1996; 175: 1286-92
20. Paarlberg K, Vingerhoets J, Passchier J, et al. Psychosocial predictors of low birthweight: a prospective study. Br J Obstet Gynaecol 1999; 106: 834-41
21. Wadhwa P, Sandman C, Porto M, et al. The association between prenatal stress and infant birth weight and gestational age at birth: a prospective investigation. Am J Obstet Gynecol 1993; 169: 858-65
22. Hedegaard M, Henriksen T, Secher N, et al. Do stressful life events affect duration of gestation and risk of preterm delivery? Epidemiology 1996; 7: 339-45
23. Lobel M, Dunkel-Schetter C, Scrimshaw S. Prenatal maternal stress and prematurity: a prospective study of socioeconomically disadvantaged women. Health Psychol 1992; 11: 32-40
24. Reeb K, Graham A, Zyzanski S, et al. Predicting low birthweight and complicated labor in urban black women: a biopsychosocial perspective. Soc Sci Med 1987; 25: 1321-7
25. Marcus S, Barry K, Flynn H, et al. Treatment guidelines for depression in pregnancy. Int J Gynaecol Obstet 2001; 72: 61-70
26. Ward R, Zamorski M. Benefits and risks of psychiatric medications during pregnancy. Am Fam Physician 2002; 15: 629-36
27. Nonacs R, Cohen L. Depression during pregnancy: diagnosis and treatment options. J Clin Psychiatry 2002; 63: 24-30
28. Altshuler L. The use of SSRIs in depressive disorders specific to women. J Clin Psychiatry 2002; 63: 3-8
29. Newport D, Wilcox M, Stowe Z. Antidepressants during pregnancy and lactation: defining exposure and treatment issues. Semin Perinatol 2001; 25: 177-90
30. Wisner K, Gelenberg A, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999; 282: 1264-9
31. Grush L, Cohen L. Treatment of depression during pregnancy: balancing the risks. Harv Rev Psychiatry 1998; 6: 105-9
32. Yonkers K, Wisner K, Stowe Z, et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 2004; 161: 608-20
33. Cox JL, Holden JM, Sagovsky R. Detection of postnatal depression: development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry 1987; 150: 782-6
34. Murray L, Cox J. Screening for depression during pregnancy with the Edinburgh postnatal depression scale (EPDS). J Reprod Infant Psychol 1990; 8: 99-107
35. Eberhard-Gran M, Eskild A, Tambs K, et al. Review of validation studies of the Edinburgh Postnatal Depression Scale. Acta Psychiatr Scand 2001; 104: 243-9
36. O'Hara MW, Zekoski E. Postpartum depression: a comprehensive review. In: Kumar R, Brockington I, editors. Motherhood and mental illness. London: Wright, 1988: 17-63
37. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Press, 1994
38. Altshuler L, Hendrick V. Pregnancy and psychotropic medication. J Clin Pharmacol 1996; 16: 78-80
39. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry 1993; 150: 1541-2
40. Levy G. Pharmacokinetics of fetal and neonatal exposure to drugs. Obstet Gynecol 1981; 58 (5 Suppl.): 9S-16S
41. Cohen L, Rosenbaum J. Psychotropic drug use during pregnancy: weighing the risks. J Clin Psychiatry 2003; 59: 18-28
42. Hendrick V, Altshuler L. Management of major depression during pregnancy. Am J Psychiatry 2002; 159: 1667-73
43. Moore K. The developing human: clinically oriented embryology. 6th ed. Philadelphia (PA): WB Saunders Co, 1998
44. Elkin I, Shea M, Watkins J, et al. National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Arch Gen Psychiatry 1989; 46: 971-82
45. Oren D, Wisner K, Spinelli M, et al. An open trial of morning light therapy for treatment of antepartum depression. Am J Psychiatry 2002; 159: 666-9
46. Spinelli M, Endicott J. Controlled clinical trial of interpersonal psychotherapy versus parenting education program for depressed pregnant women. Am J Psychiatry 2003; 160: 555-62
47. Rabheru K. The use of electroconvulsive therapy in special patient populations. Can J Psychiatry 2001; 46: 710-9
48. Miller L. Use of electroconvulsive therapy during pregnancy. Hosp Community Psychiatry 1994; 45: 444-50
49. Moreno M, Munoz J, Valderrabanos J, et al. Electroconvulsive therapy in first trimester of pregnancy. J ECT 1998; 4: 251-4
50. Stokes P, Holtz A. Fluoxetine tenth anniversary update: the progress continues. Clin Ther 1997; 19: 1135-250
51. Kulin N, Pastuszak A, Sage S, et al. Pregnancy outcome following maternal use of new selective seretonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279: 609-10
52. Altshuler L, Cohen L, Szuba M, et al. Pharmacologic manage-ment of psychiatric illness during pregnancy: dilemmas and guidelines. Am J Psychiatry 1996; 153: 592-606
53. McElhatton P, Garbis H, Elefant E, et al. The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants: a collaborative study of the European Network of Teratology Information Services (ENTIS). Reprod Toxicol 1996; 10: 285-94
54. Nulman I, Rovert J, Stewart D, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997; 336: 258-362
55. Ericson A, Kallen B, Wiholm B. Delivery outcome after the use of antidepressants in early pregnancy. Eur J Pharmacol 1999; 55: 503-8
56. Chambers C, Johnson K, Dick L, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 1010-5
57. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269: 2246-8
58. Goldstein D, Corbin L, Sundell K. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997; 89: 713-8
59. Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: a meta-analytical review of epidemiological studies. Psychol Med 2000; 30: 89-94
60. Robert E. Treatment depression in pregnancy. N Engl J Med 1996; 335: 1056-8
61. Nordeng H, Lindemann R, Perminov K, et al. Neonatal with-drawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Pædiatr 2001; 90: 288-91
62. Dahl M, Olhager E, Ahlner J. Paroxetine withdrawal syndrome in a neonate. Br J Psychiatry 1997; 171: 391-2
63. Nijhuis I, Kok-Van Rooij G, Bosschaart A. Withdrawal reactions of a premature neonate after maternal use of paroxetine [letter]. Arch Dis Child Fetal Neonatal Ed 2001; 84: F77
64. Spencer M. Fluoxetine hydrochloride (Prozac) toxicity in a neonate. Pediatrics 1993; 92: 721-2
65. Mhanna M, Bennet JI, Izatt S. Potential fluoxetine chloride (Prozac) toxicity in a newborn. Pediatrics 1997; 100: 158-9
66. Kent L, Laidlaw J. Suspected congenital sertraline dependence. Br J Psychiatry 1995; 167: 412-3
67. American Academy of Pediatrics. Committee on drugs: neonatal drug withdrawal. Pediatrics 1998; 101: 1079-88
68. Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003; 60: 720-6
69. Costei A, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002; 156: 1129-32
70. Cohen L, Heller A, Bailey J, et al. Birth outcome following prenatal exposure to fluoxetine. Biol Psychiatry 2000; 48: 996-1000
71. Casper R, Fleisher B, Lee-Ancajas J, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003; 142: 402-8
72. Simon G, Cunningham M, Davis R. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 2055-61
73. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004; 158: 312-6
74. Duijvestijn Y, Kalmeijer M, Passier A, et al. Neonatal intraventricular haemorrhage associated with maternal use of paroxetine. Br J Clin Pharmacol 2003; 56: 581-2
75. Heikkinen T, Ekblad U, Palo P, et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregancy and lactation. Clin Pharmacol Ther 2003; 73: 330-7
76. Nulman I, Rovet J, Stewart D, et al. Child development following exposure to tricyclic antidepressants or fluoxetine through-out fetal life: a prospective, controlled study. Am J Psychiatry 2002; 159: 1889-95
77. Heikkinen T, Ekblad U, Kero P, et al. Citalopram in pregnancy and lactation. Clin Pharmacol Ther 2002; 72: 184-91
78. Zeskind P, Stephens L. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004; 113: 368-75
79. The National Toxicology Program (NTP). Center for Evaluation of Risks to Human Reproduction (CERHR). Monograph on the potential human reproductive effects of fluoxetine: appendix II: 143, 2004 Nov [online]. Available from URL: http://www.cerhr.niehs.nih.gov [Accessed 2004 Dec 1]
80. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991; 21: 157-71
81. Loebstein R, Koren G. Pregnancy outcome and neurodevelopment of children exposed in utero to psychoactive drugs: the Motherisk experience. J Psychiatry Neurosci 1997; 22: 192-6
82. Bromiker R, Kaplan M. Apparant intrauterine fetal withdrawal from chlomipramine hydrochloride. JAMA 1994; 272: 1722-3
83. Cowe L, Lloyd D, Dawling S. Neonatal convulsions caused by withdrawal from maternal clomipramine. BMJ 1982; 284: 1837-8
84. Eggermont E. Withdrawal symptoms in neonates associated with maternal imipramine therapy [letter]. Lancet 1973; II: 680
85. Schimmell M, Katz E, Shaag Y, et al. Toxic neonatal effects following maternal clomipramine therapy. J Toxicol Clin Toxicol 1991; 29: 479-84
86. Webster P. Withdrawal symptoms in neonates associated with maternal antidepressant therapy. Lancet 1973; II: 318-9
87. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxin: a multicenter prospective controlled study. Am J Psychiatry 2001; 158: 1728-30
88. Heinonen O, Slone D, Shapiro S. Birth defects and drugs in pregnancy. Littleton (MA): Publishing Services Group, 1977
89. Cooper AJ. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry Suppl 1989; (6): 38-45
90. Shade RJ, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Eng J Med 1993; 328: 1398-405
91. Dolovich L, Addis A, Vaillancourt J, et al. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998; 317: 839-43
92. Iqbal M, Sobhan T, Ryals T. Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant. Psychiatr Serv 2002; 53: 39-49
93. McElhatton P. The effects of benzodiazepine use during pregnancy and lactation. Reprod Toxicol 1994; 8: 461-75
94. McGrath C, Buist A, Norman T. Treatment of anxiety during pregnancy. Drug Saf 1999; 20: 171-86
95. Viggedal G. Mental development in late infancy after prenatal exposure to benzodiazepines: a prospective study. J Child Psychol Psychiatry 1993; 34: 295-305
96. Nesse R, Zamorski M. Anxiety disorders in primary care. In: Knesper D, Riba M, Schwenk T, editors. Primary care psychiatry. Philadelphia (PA): Saunders, 1997: 132-162
97. Cohen L, Friedman J, Jefferson J, et al. A reevaluation of risk of in utero exposure to lithium. JAMA 1994; 271: 146-50
98. Troyer W, Pereira G, Lannon R, et al. Association of maternal lithium exposure and premature delivery. J Perinatol 1993; 13: 123-7
99. Stewart D, Klompenhouwer J, Kendell R, et al. Prophylactic lithium in puerperal psychosis: the experience of three centres. Br J Psychiatry 1991; 158: 393-7
100. Wisner K, Perel J. Psychopharmacological treatment during pregnancy. In: Jensvold M, Halbreich U, Hamilton J, editors. Psychopharmacology and women: sex, gender and hormones. Washington, DC: American Psychiatric Press, 1996: 191-224
101. Sitland-Marken P, Rickman L, Wells B, et al. Pharmacological management of acute mania in pregnancy. J Clin Psychopharmacol 1989; 9: 78-87
102. Schou M. What happened later to the lithium babies? A follow-up study of children born without malformations. Acta Psychiatr Scand 1976; 54: 193-7
103. Schou M. Treating recurrent affective disorders during and after pregnancy. Drug Saf 1998; 18: 143-52
104. Rosa F. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991; 324: 674-7
105. Delgado-Escueta A, Janz D. Consensus guidelines: preconception counseling, management and care of the pregnant woman with epilepsy. Neurology 1992; 45 Suppl. 5: 149-60
106. Shaw G, Wasserman C, O'Malley C, et al. Orofacial clefts and maternal anticonvulsant use. Reprod Toxicol 1995; 9: 97-8
107. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338: 131-7
108. Kennedy D, Koren G. Valproic acid use in psychiatry: issues in treating women of reproductive age. J Psychiatry Neurosci 1998; 23: 223-8
109. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996; 75: 517-20
110. Scolnik D, Nulman I, Rovet J, et al. Neurodevelopment of children exposed in utero to phenytoin and carbamazepine monotherapy. JAMA 1994; 271: 767-70
111. Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004; 62: 28-32
112. Shapiro S, Slone D, Hartz S. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1976; I: 272-5
113. Gaily E, Kantola-Sorsa E, Granström M. Intelligence of children of epileptic mothers. J Pediatr 1988; 113: 677-84
114. Holmes L, Rosenberger P, Harvey E. An evaluation of whether maternal epilepsy (no drugs) is associated with an increased rate of cognitive dysfunction [abstract 37]. Teratology 1995; 51: 165
115. GlaxoSmithKline. Lamotrigine Pregnancy Registry. Interim report: 1 September 1992 through 31 March 2004
116. Sabers A, Dam M, A-Rogvi-Hansen B, et al. Epilepsy and pregnancy: lamotrigine as main drug used. Acta Neurol Scand 2004; 109: 9-13
117. Goldstein D. Olanzapine-exposed pregnancies and lactation: early experience. J Clin Psychopharmacol 2000; 20: 399-403
118. Littrell K, Johnson C, Peabody C, et al. Antipsychotics during pregnancy [letter]. Am J Psychiatry 2000; 157: 1342